NBTXR3 Radiation Enhancing Hafnium Oxide Nanoparticles Activated By Radiotherapy In Combination With Anti-PD-1 Therapy: A Phase I Study
Colette J. Shen(Johns Hopkins University), Tanguy Y. Seiwert(Georgetown University), Jessica M. Frakes(Moffitt Cancer Center), Alexander T. Pearson(University of Chicago), Yun Hu(Stomatology Hospital), R. D. Dixon(University at Buffalo, State University of New York), Ghassan El‐Haddad(Moffitt Cancer Center), K. Jameson, Jason Akulian(University of North Carolina at Chapel Hill), Trevor Hackman(University of North Carolina at Chapel Hill), James W. Welsh(The University of Texas MD Anderson Cancer Center), J.J. Caudell(Moffitt Cancer Center), Patricia Said(Nanobiotix (France)), María Angélica Cortez(The University of Texas MD Anderson Cancer Center), H. Barsoumian(The University of Texas MD Anderson Cancer Center)
International Journal of Radiation Oncology*Biology*Physics
October 23, 2020
Cited by 4
Related Papers
IFN-γ–related mRNA profile predicts clinical response to PD-1 blockade
|Journal of Clinical Investigation|2017|3.9k
Phase 3 Trial of <sup>177</sup> Lu-Dotatate for Midgut Neuroendocrine Tumors
|New England Journal of Medicine|2017|3.2k
Deep learning can predict microsatellite instability directly from histology in gastrointestinal cancer
|Nature Medicine|2019|1.4k